The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | DELIVER: nivolumab in advanced gastric cancer

Name: DELIVER: nivolumab in advanced gastric cancer
Uploaded: 2020-06-28T00:00:00Z
Duration: 6 min 10 s
Description: Yu Sunakawa, MD, PhD, of St. Marianna University School of Medicine, Kawasaki, Japan, outlines an updated analysis of the DELIVER trial (JACCRO GC-08), evaluating nivolumab in advanced gastric cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Yu Sunakawa • 28 Jun 2020

ESMO WCGIC 2020

Gastric Cancer Gastrointestinal Cancer Antibodies Nivolumab

DELIVER

Yu Sunakawa, MD, PhD, of St. Marianna University School of Medicine, Kawasaki, Japan, outlines an updated analysis of the DELIVER trial (JACCRO GC-08), evaluating nivolumab in advanced gastric cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).